Table 1 Emetic risk groups according to MASCC

High

Cisplatin, mechlorethamine, streptozocin, cyclophosphamide >1,500 mg/m², carmustine, dacarbazin

Oral: Hexamethylmelamine, procarbazine

Moderate

Oxaliplatin, cytarabine >1,000 mg/m², carboplatin, ifosfamide, cyclophosphamide <1,500 mg/m², azacitidine, alemtuzumab, doxorubicin, daunorubicin, epirubicin, idarubicin, irinotecan, bendamustine, clofarabine

Oral: Cyclophosphamide, temozolomide, vinorelbine, imatinib

Low

Paclitaxel, docetaxel, mitoxantrone, topotecan, etoposide, pemetrexed, methotrexate, doxorubicin HCl liposome injection, temsirolimus, ixabepilone, mitomycin, gemcitabine, cytarabine <1,000 mg/m², 5-fluorouracil, bortezomib, cetuximab, trastuzumab, catumaxomab, panitumumab

Oral: Capecitabine, tegafur uracil, etoposide, sunitinib, fludarabine, everolimus, lapatinib, lenalidomide, thalidomide

Minimal

Bleomycin, busulfan, cladribine, fludarabine, vinblastine, vincristine

vinorelbine, bevacizumab

Oral: chlorambucil, hydroxyurea, melphalan, methotrexate, 6-thioguanine

gefitinib, sorafenib, erlotinib